These benefits, together with a prior report demonstrating that a small-molecule ACKR3 agonist CCX771 displays anxiolytic-like conduct in mice,2 guidance the thought of concentrating on ACKR3 as a singular strategy to modulate the opioid process, which could open new therapeutic avenues for opioid-relevant Diseases.A whole new research shows which